News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
279,276 Results
Type
Article (14763)
Company Profile (301)
Press Release (264206)
Multimedia
Podcasts (71)
Webinars (11)
Section
Business (79767)
Career Advice (157)
Deals (13306)
Drug Delivery (38)
Drug Development (50650)
Employer Resources (31)
FDA (5819)
Job Trends (5163)
News (144946)
Policy (10065)
Tag
Academia (918)
Accelerated approval (14)
Adcomms (14)
Allergies (73)
Alliances (21761)
ALS (111)
Alzheimer's disease (1006)
Antibody-drug conjugate (ADC) (208)
Approvals (5955)
Artificial intelligence (229)
Autoimmune disease (88)
Automation (9)
Bankruptcy (105)
Best Places to Work (4560)
BIOSECURE Act (6)
Biosimilars (90)
Biotechnology (231)
Bladder cancer (92)
Brain cancer (41)
Breast cancer (303)
Cancer (2832)
Cardiovascular disease (217)
Career advice (143)
Career pathing (5)
CAR-T (203)
CDC (5)
Cell therapy (529)
Cervical cancer (13)
Clinical research (43192)
Collaboration (977)
Company closure (2)
Compensation (522)
Complete response letters (32)
COVID-19 (1089)
CRISPR (80)
C-suite (458)
Cystic fibrosis (106)
Data (3893)
Denatured (13)
Depression (78)
Diabetes (229)
Diagnostics (1359)
Digital health (9)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (155)
Drug pricing (42)
Drug shortages (3)
Duchenne muscular dystrophy (196)
Earnings (31527)
Editorial (23)
Employer branding (4)
Employer resources (29)
Events (51250)
Executive appointments (608)
FDA (7321)
Fibrodysplasia Ossificans Progressiva (4)
Friedreich's ataxia (6)
Frontotemporal dementia (19)
Funding (876)
Gene editing (167)
Generative AI (18)
Gene therapy (441)
GLP-1 (480)
Government (1135)
Grass and pollen (3)
Guidances (162)
Healthcare (6608)
HIV (14)
Huntington's disease (37)
IgA nephropathy (68)
Immunology and inflammation (171)
Immuno-oncology (19)
Indications (46)
Infectious disease (1184)
Inflammatory bowel disease (147)
Inflation Reduction Act (10)
Influenza (34)
Intellectual property (146)
Interviews (18)
IPO (7332)
IRA (12)
Job creations (867)
Job search strategy (129)
Kidney cancer (9)
Labor market (22)
Layoffs (240)
Leadership (8)
Legal (1397)
Liver cancer (38)
Longevity (9)
Lung cancer (400)
Lymphoma (234)
Machine learning (21)
Management (7)
Manufacturing (317)
MASH (123)
Medical device (2651)
Medtech (2657)
Mergers & acquisitions (6526)
Metabolic disorders (645)
Multiple sclerosis (90)
NASH (13)
Neurodegenerative disease (201)
Neuropsychiatric disorders (60)
Neuroscience (1809)
NextGen: Class of 2025 (2030)
Non-profit (859)
Now hiring (28)
Obesity (282)
Opinion (120)
Ovarian cancer (120)
Pain (85)
Pancreatic cancer (132)
Parkinson's disease (201)
Partnered (11)
Patents (269)
Patient recruitment (259)
Peanut (41)
People (26446)
Pharmaceutical (46)
Pharmacy benefit managers (6)
Phase I (15289)
Phase II (20083)
Phase III (12684)
Pipeline (2314)
Policy (84)
Postmarket research (853)
Preclinical (6504)
Press Release (30)
Prostate cancer (131)
Psychedelics (47)
Radiopharmaceuticals (222)
Rare diseases (550)
Real estate (1445)
Recruiting (12)
Regulatory (9566)
Reports (19)
Research institute (965)
Resumes & cover letters (18)
Rett syndrome (20)
RNA editing (16)
RSV (16)
Schizophrenia (111)
Series A (160)
Series B (119)
Service/supplier (1)
Sickle cell disease (73)
Special edition (17)
Spinal muscular atrophy (118)
Sponsored (14)
Startups (1997)
State (1)
Stomach cancer (5)
Supply chain (30)
Tariffs (17)
The Weekly (57)
Vaccines (311)
Venture capital (53)
Weight loss (157)
Women's health (22)
Worklife (2)
Date
Today (101)
Last 7 days (405)
Last 30 days (1587)
Last 365 days (18177)
2025 (17452)
2024 (20547)
2023 (22414)
2022 (26822)
2021 (27806)
2020 (23357)
2019 (16224)
2018 (11738)
2017 (13745)
2016 (11839)
2015 (14349)
2014 (10392)
2013 (7484)
2012 (7532)
2011 (7614)
2010 (7429)
Location
Africa (153)
Alabama (61)
Alaska (2)
Arizona (61)
Arkansas (5)
Asia (18051)
Australia (3071)
California (6534)
Canada (1732)
China (671)
Colorado (227)
Connecticut (233)
Delaware (212)
Europe (38803)
Florida (818)
Georgia (198)
Hawaii (2)
Idaho (17)
Illinois (358)
India (31)
Indiana (147)
Iowa (8)
Japan (185)
Kansas (79)
Kentucky (9)
Louisiana (7)
Maine (11)
Maryland (701)
Massachusetts (5166)
Michigan (101)
Minnesota (230)
Mississippi (3)
Missouri (31)
Montana (15)
Nebraska (4)
Nevada (29)
New Hampshire (18)
New Jersey (1545)
New Mexico (12)
New York (1641)
North Carolina (777)
North Dakota (6)
Northern California (3161)
Ohio (166)
Oklahoma (11)
Oregon (22)
Pennsylvania (1194)
Puerto Rico (8)
Rhode Island (25)
South America (210)
South Carolina (9)
Southern California (2573)
Tennessee (37)
Texas (830)
United States (21635)
Utah (89)
Virginia (129)
Washington D.C. (36)
Washington State (540)
West Virginia (1)
Wisconsin (32)
279,276 Results for "medeor therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Pharm Country
Medeor Therapeutics Announces Interim Data from Pivotal Trial Showing Cell Therapy Technology Could Eliminate Life-Long Need for Immunosuppressant Drugs Following Kidney Transplant
Medeor Therapeutics announced positive interim data from its multicenter, international Phase III clinical trial.
November 2, 2023
·
5 min read
Biotech Bay
Medeor Therapeutics to Present Interim Pivotal Data on MDR-101 Cell Therapy for Induction of Immune Tolerance and Elimination of Immunosuppressants Following Kidney Transplant in Late Breaker Oral Presentation at ASN Kidney Week 2023
Medeor Therapeutics announced that it will present interim Phase 3 data investigating if MDR-101 cell therapy can safely induce immune tolerance and eliminate the need for immunosuppressive drugs vs. standard of care following a kidney transplant as a late-breaking oral presentation at the American Society of Nephrology Kidney Week, November 1-5, 2023 in Philadelphia, Pennsylvania.
October 25, 2023
·
1 min read
Press Releases
Flagship Pioneering Announces New Agreements with ProFound Therapeutics and Quotient Therapeutics Under its Collaboration with GSK
November 21, 2025
·
5 min read
Drug Development
Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants
Medeor Therapeutics Completes Enrollment and Transplantation for Pivotal Trial of MDR-101 Cell Therapy to Establish Tolerance in HLA-Matched Living Donor Kidney Transplants
May 12, 2021
·
3 min read
Press Releases
Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition
November 26, 2025
·
5 min read
Business
Medeor Therapeutics Appoints Dr. Daniel Brennan as Chief Medical Officer
Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced the appointment of Daniel Brennan, MD, as Chief Medical Officer. In his role, Dr. Brennan will oversee the clinical development program fo
October 14, 2020
·
2 min read
FDA
Medeor Therapeutics’ Transplant Immune Tolerance Therapy Receives Regenerative Medicine Advanced Therapy Designation from FDA
Medeor Therapeutics, Inc. , a clinical-stage company dedicated to the development and commercialization of immunotherapies for transplantation, today announced that the U.S. Food and Drug Administration (FDA) has granted a Regenerative Medicine Advanced Therapy (RMAT) designation to MDR-101, Medeor’s therapy designed to enable immune tolerance in kidney transplant patients, thereby eliminating the need for
September 22, 2020
·
2 min read
Press Releases
Halda Therapeutics Announces Acquisition by Johnson & Johnson
November 18, 2025
·
3 min read
Press Releases
Courage Therapeutics Appoints Biopharma Leader Giovanni Ferrara as CEO
June 13, 2025
·
3 min read
Press Releases
Avenue Therapeutics Announces Acquisition of Subsidiary Baergic Bio by Axsome Therapeutics
November 6, 2025
·
7 min read
1 of 27,928
Next